Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence ApproachRelease Date:Research Inflammation & Immunology USA Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUCEducation Oncology USA Advancing Genomic Competence and Patient Centered Care in Metastatic Breast CancerRelease Date:Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction ManagementRelease Date:Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positRelease Date:Education Oncology United States Minor Outlying I OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic MalignanciesRelease Date:Quality Improvement Oncology China Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory OutcomeRelease Date:Education Vaccines USA Implementing Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease USA Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Fellowship Internal Medicine Germany Title Grant Type Focus Area Country Application Due Date Innovative Digital Health Projects to increase the Quality of Life (QoL) of Multiple Myeloma (MM) patientsRelease Date:Quality Improvement Oncology Italy 2024 RD Global Monitoring anti-TFPI RESRelease Date:Research Rare Disease All Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)Education Oncology All Health Services Research to Improve Management of mBC Patients Treated with TucatinibRelease Date:Research Oncology All Addressing Multiple Myeloma Gaps in Care for Patients in Latin AmericaRelease Date:Partner: International Myeloma FoundationEducation Oncology Argentina, Brazil, Colombia, Mexico Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Management of Atopic Dermatitis / Alopecia AreataRelease Date:Education Inflammation & Immunology USA Improving the Care Process for Patients with Advanced Prostate CancerRelease Date:Partner: The American Urological Association Education and Research, Inc.; AstellasQuality Improvement Oncology USA Optimizing Care for patients with locally advanced or metastatic Urothelial Carcinoma (la/mUC)Release Date:Quality Improvement Oncology Canada Prospective Surveillance and Burden of Disease for RSV-Related Respiratory Tract Infections in Taiwanese Pediatric PopulationRelease Date:Research Vaccines Taiwan PARP-Inhibitor Combination Therapies: Personalized Treatment for Patients with Metastatic Castration-Resistant Prostate CancerRelease Date:Education Oncology Canada Developing Educational Initiatives for ALK+ Metastatic Non-small Cell Lung Cancer Tyrosine Kinase Inhibitors TherapyRelease Date:Education Oncology Canada